Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Introduction: Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss and fatigue. Reduced doses may be suboptimal in slowing disease progression. Methods: This phase 1b, randomised, open-label, dose–response trial at 25 sites in six countries (Australian New Zealand Clinical Trials Registry (ANZCTR) registration number ACTRN12618001838202) assessed safety, tolerability and efficacy of inhaled pirfenidone (AP01) in IPF. Patients diagnosed within 5 years, with forced vital capacity (FVC) 40%–90% predicted, and intolerant, unwilling or ineligible for oral pirfenidone or nintedanib were randomly assigned 1:1 to nebulised AP01 50 mg once per day or 100 mg two times per day for up to 72 weeks. Results: We present results for week 24, the primary endpoint and week 48 for comparability with published trials of antifibrotics. Week 72 data will be reported as a separate analysis pooled with the ongoing open-label extension study. Ninety-one patients (50 mg once per day: n=46, 100 mg two times per day: n=45) were enrolled from May 2019 to April 2020. The most common treatment-related adverse events (frequency, % of patients) were all mild or moderate and included cough (14, 15.4%), rash (11, 12.1%), nausea (8, 8.8%), throat irritation (5, 5.5%), fatigue (4, 4.4%) and taste disorder, dizziness and dyspnoea (three each, 3.3%). Changes in FVC % predicted over 24 and 48 weeks, respectively, were −2.5 (95% CI −5.3 to 0.4, −88 mL) and −4.9 (−7.5 to −2.3,–188 mL) in the 50 mg once per day and 0.6 (−2.2 to 3.4, 10 mL) and −0.4 (−3.2 to 2.3, −34 mL) in the 100 mg two times per day group. Discussion: Side effects commonly associated with oral pirfenidone in other clinical trials were less frequent with AP01. Mean FVC % predicted remained stable in the 100 mg two times per day group. Further study of AP01 is warranted. Trial registration number: ACTRN12618001838202 Australian New Zealand Clinical Trials Registry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“ATLAS-OLE demonstrated a high rates of photosensitivity, 22% and 20% at doses 50 mg twice daily and 100 mg twice daily respectively, as opposed to 30% in historical oral pirfendone group [40].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [40]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RECAP, a large open-label continuation study of pirfenidone for IPF, included 1,058 patients treated with 2,403 mg/day of pirfenidone or the highest tolerated dose (≤2,403 mg/day) for up to 349 weeks and demonstrated pirfenidone’s continued efficacy and safety [25,26].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Quanjer, P. H., Stanojevic, S., Cole, T. J., Baur, X., Hall, G. L., Culver, B. H., Enright, P. L., Hankinson, J. L., Ip, M. S. M., Zheng, J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00080312 · Cited by 5,919
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Birring, S. S. (2003) · Thorax · doi:10.1136/thorax.58.4.339 · Cited by 1,062
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
Self-citation
Research works printed but not linked: 3
- 1. West A, et al. Thorax 2023;78:882-889. doi:10.1136/thorax-2022-219391 Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. . by guest on December 20, 2025 http://thorax.bmj.com/ Downloaded from 22 March 2023. 10.1136/thorax-2022-219391 on Thorax: first published as Interstitial lung disease Bellerophon Therapeutics, Biogen, Bristol Myers Squibb, Fibrogen, Nitto, Promedior, Respivant and Veracyte.
- 10. Lalla D, Bengston L, Raimundo K, et al. Pirfenidone and nintedanib compliance and persistence in A real world setting. Am J Respir Crit Care Med 2017;195:A5351.
- 28. West A, et al. Thorax 2023;78:882-889. doi:10.1136/thorax-2022-219391 Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. . by guest on December 20, 2025 http://thorax.bmj.com/ Downloaded from 22 March 2023. 10.1136/thorax-2022-219391 on Thorax: first published as
Cited by
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
PI3K/Akt in IPF: untangling fibrosis and charting therapies
Bhatt, J., Ghigo, A., & Hirsch, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1549277 · Cited by 41
Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases
Yong, J., Shu, H., Zhang, X., Yang, K., Luo, G., Yu, L., Li, J., & Huang, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s451206 · Cited by 38
A new era in the treatment of progressive fibrosing interstitial lung diseases
Denis, A., Tsiri, P., Guiot, J., & Τzouvelekis, Α. (2025) · Breathe · doi:10.1183/20734735.0259-2024 · Cited by 38
Wang, Y., Xuan, W., Mao, C., & Liu, Y. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.07.068 · Cited by 31
Metadata
- Authors
- West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., Wijsenbeek, M. S., Grainge, C., Piotrowski, W., Raghu, G., Shaffer, M. L., Nair, D., Freeman, L., Otto, K., & Montgomery, A. B.
- Affiliations
- Guy's Hospital (GB)
- University of Ulster (GB)
- Medical University of Silesia (PL)
- Auckland District Health Board (NZ)
- Prince Charles Hospital (AU)
- The Alfred Hospital (AU)
- Royal Prince Alfred Hospital (AU)
- Thomayer University Hospital (CZ)
- Gdańsk Medical University (PL)
- Erasmus MC (NL)
- Hunter Medical Research Institute (AU)
- Medical University of Lodz (PL)
- University of Washington (US)
- Corresponding author
- Montgomery, A Bruce
- ORCID
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2023-03-22
- Volume
- 78
- Issue
- 9
- Pages
- 882-889
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W4353042437
- Cited by
- 67
- References
- 23
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 19 · 2023: 6
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Thorax (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Ulster University Research Portal (Ulster University) (acceptedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Avalyn Pharma (Not applicable)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, pulmonary drug delivery, antifibrotic therapy, forced vital capacity decline, lung function, dose-response relationship, safety and tolerability, nintedanib
- MeSH terms
- Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Australia, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial. https://app.cochat.ai/papers/10.1136/thorax-2022-219391
- The paper
- West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., Wijsenbeek, M. S., Grainge, C., Piotrowski, W., Raghu, G., Shaffer, M. L., Nair, D., Freeman, L., Otto, K., & Montgomery, A. B. (2023). Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial. Thorax. https://doi.org/10.1136/thorax-2022-219391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.